All In Biotech

Drug Trial Radar · NCT06347133

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,456 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,456

Actual

Start

May 21, 2024

Primary completion

Jun 1, 2026

Study completion Sep 8, 2026

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.

Conditions

  • Hypertriglyceridemia

Interventions

  • Plozasiran InjectionDrug

    ARO-APOC3 Injection

  • PlaceboDrug

    sterile normal saline (0.9% NaCl)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to PlaceboTime frame: Baseline, Month 12

Locations

235 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site 1

    Birmingham, Alabama

  • Research Site 2

    Mobile, Alabama

  • Research Site 3

    Beverly Hills, California

  • Research Site 4

    Canoga Park, California

  • Research Site 5

    Garden Grove, California

  • Research Site 6

    Huntington Beach, California

  • Research Site 7

    Lake Forest, California

  • Research Site 8

    Lincoln, California

  • Research Site 9

    Long Beach, California

  • Research Site 10

    Montclair, California

  • Research Site 11

    Oxnard, California

  • Research Site 12

    Redding, California

  • Research Site 13

    Van Nuys, California

  • Research Site 14

    Colorado Springs, Colorado

  • Research Site 15

    Clearwater, Florida

  • Research Site 16

    Hialeah, Florida

  • Research Site 17

    Lake City, Florida

  • Research Site 18

    Miami Lakes, Florida

  • Research Site 19

    Mt. Dora, Florida

  • Research Site 20

    North Miami Beach, Florida

  • Research Site 21

    Orlando, Florida

  • Research Site 22

    Pensacola, Florida

  • Research Site 23

    Sarasota, Florida

  • Research Site 24

    Tamarac, Florida

  • Research Site 25

    Lawrenceville, Georgia

  • Research Site 26

    Macon, Georgia

  • Research Site 27

    Savannah, Georgia

  • Research Site 28

    Sugar Hill, Georgia

  • Research Site 29

    Park Ridge, Illinois

  • Research Site 30

    Elkhart, Indiana

  • Research Site 31

    Indianapolis, Indiana

  • Research Site 32

    South Bend, Indiana

  • Research Site 33

    Overland Park, Kansas

  • Research Site 34

    Topeka, Kansas

  • Research Site 35

    Louisville, Kentucky

  • Research Site 36

    Zachary, Louisiana

  • Research Site 37

    Annapolis, Maryland

  • Research Site 38

    Baltimore, Maryland

  • Research Site 39

    Flint, Michigan

  • Research Site 40

    Minneapolis, Minnesota

Showing 40 of 235 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.